Enzalutamide versus Abiraterone Acetate as first-line treatment of castration resistant metastatic prostate cancer in geriatric (≥75) patients

Enzalutamide versus Abiraterone Acetate as first-line treatment of castration resistant metastatic prostate cancer in geriatric (≥75) patients

Introduction: The efficacy and tolerability of Enzalutamide and Abiraterone Acetate have been reported in elderly patients with metastatic castration resistant prostate cancer (mCRPC). However, there is no randomized study directly comparing antitumor effects between these 2 agents in geriatric...

Full description

Bibliographic Details
Main Authors: Ali Alkan, Zeynep Gülsüm Güç, Mustafa Gürbüz, Güliz Özgün, Serkan Değirmencioğlu, Mutlu Doğan, Tuğba Akın Telli, Özge Keskin, Çağatay Arslan, Burak Bilgin, Sema Sezgin Göksu, Hacer Demir, Elif Berna Köksoy, Osman Köstek, İsmail Ertürk, Teoman Şakalar, Arzu Yaşar, Görkem Türkkan, Büşra Kasım, Aziz Karaoğlu, Berna Çakmak Öksüzoğlu, Fulden Yumuk, Mehmet Ali Şendur, Hasan Şenol Coşkun, İrfan Çiçin, Nuri Karadurmuş, Özgür Tanrıverdi, Hakan Akbulut, Yüksel Ürün
Format: Article
Language:English
Published: MRE Press 2021-09-01
Series:Journal of Men's Health
Subjects:
metastatic castration-resistant prostate cancer
enzalutamide
abiraterone acetate
elderly
Online Access:https://oss.jomh.org/jomh/article/20210928-455/pdf/JOMH2021011801.pdf

Internet

https://oss.jomh.org/jomh/article/20210928-455/pdf/JOMH2021011801.pdf

Similar Items